Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMSCGM8)

Drug Name	LentiGlobin DMSCGM8
Synonyms	Globin gene therapy (LentiPak, sickle cell/beta-thalassemia), Genetix; Globin gene therapy (LentiPak, sickle cell/beta-thalassemia), bluebird

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Beta thalassemia	DIS5RCQK	3A50.2	Phase 3	[1]
------------------------------------------------------------------------------------

1 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Sickle-cell disorder	DISW25G5	3A51	Phase 1	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03207009) A Study Evaluating the Efficacy and Safety of the LentiGlobin BB305 Drug Product in Subjects With Transfusion-Dependent beta-Thalassemia. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)